Welcome to our dedicated page for Nuwellis SEC filings (Ticker: NUWE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Nuwellis, Inc. (Nasdaq: NUWE), a medical technology and medical device company focused on precision fluid management for patients with cardio-renal conditions and fluid overload. Through these filings, investors can review how Nuwellis reports its financial performance, material events, and key developments related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Current report filings (Form 8-K) for Nuwellis often cover topics such as quarterly financial results, changes in executive roles, new patents, NIH grant-supported programs, FDA 510(k) clearances for accessories like catheters, and at-the-market equity offering agreements. Some 8-K filings also reference press releases announcing clinical registry findings, such as the ULTRA-Peds pediatric Aquadex registry, or new intellectual property supporting pediatric safety features and hemolysis sensing in extracorporeal circuits.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) provide more detailed discussions of Nuwellis’ business, including its focus on fluid overload, its Aquadex SmartFlow system, development-stage technologies like Vivian, and its geographic footprint with headquarters in Minneapolis and a subsidiary in Ireland. These filings also describe risk factors, liquidity, capital-raising activities, and other information relevant to NUWE shareholders.
Stock Titan’s platform enhances these SEC documents with AI-powered summaries that explain the key points of lengthy filings, highlight important changes from prior periods, and help users quickly understand complex disclosures. Investors can also use this page to follow real-time updates as new Nuwellis filings are posted to EDGAR, including current reports, registration statements, and other material submissions related to NUWE.
Nuwellis announced a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli medical device company focused on real-time urine flow and acute kidney injury monitoring technologies. The proposed deal is described as supporting Nuwellis’s aim to expand its platform beyond ultrafiltration by potentially adding continuous renal health monitoring that can give clinicians earlier insight into fluid status and kidney function. The parties are conducting due diligence and, if they agree to proceed, the company expects the transaction to close in the fourth quarter of 2025, subject to final board approval and closing conditions. The filing also includes standard forward-looking statement disclosures noting risks such as execution, financing, integration, and other uncertainties.
Nuwellis, Inc. reported that it has released its financial results for the three and six months ended June 30, 2025. The company furnished this update through a press release dated August 14, 2025, which is attached as Exhibit 99.1. The information was provided under a current report and is treated as furnished rather than filed under securities law, which affects how it is subject to certain legal liabilities.
Nuwellis, Inc. (NUWE) filed an 8-K to report that it has regained compliance with Nasdaq’s $1.00 minimum bid-price rule. On 18 Jun 2025 the company received a deficiency notice because its shares closed below $1.00 for 30 straight trading days and, due to recent reverse splits, NUWE was ineligible for the standard 180-day cure period. Nasdaq therefore set a delisting hearing for 12 Aug 2025.
On 22 Jul 2025 Nasdaq’s Office of General Counsel informed the company that the bid-price deficiency has been cured; consequently, the hearing was cancelled and NUWE’s common stock will continue trading on the Nasdaq Capital Market. The filing eliminates an immediate delisting threat but highlights prior share-price weakness that triggered the notice.
Nuwellis, Inc. (NASDAQ: NUWE) has issued a Definitive Proxy Statement for a virtual special meeting on 4 Aug 2025. Shareholders of record on 9 Jun 2025 (130,154 shares outstanding, post-1-for-42 split) are asked to vote on four key items:
- Proposal 1 – Warrant Exercise Approval: Permit the issuance of up to 1,599,214 common shares upon exercise of Series A, Series B and underwriter warrants sold in the $5 million June 2025 financing. Warrants carry a $12.60 exercise price (cash) and a five-year term once shareholder approval is obtained; Series A warrants include a one-time price reset tied to any future reverse split, and Series B warrants allow cashless exercise.
- Proposal 2 – Authorized Share Increase: Double authorized common stock to 200 million shares to enhance capital-raising flexibility. No immediate issuance is planned, but the new shares would have rights identical to existing common stock.
- Proposal 3 – Reverse Stock Split Authority: Authorize the Board to implement, within 12 months, a split in the range of 1-for-5 to 1-for-70. The measure is intended to help the company maintain compliance with Nasdaq listing requirements should future bid-price weakness re-emerge. Fractional shares will be rounded down for cash.
- Proposal 4 – Adjournment Authority: Allow one or more adjournments if insufficient votes are received for Proposals 1-3.
Strategic Rationale
- Warrant exercise could provide up to $3.25 million of additional cash (assuming full cash exercise at current prices), supporting working-capital needs and clinical programs.
- Reverse split flexibility is positioned as a tool to protect Nasdaq listing status after previous bid-price deficiencies and repeated reverse splits (1-for-35 in Jun 2024 and 1-for-42 in Jul 2025).
- Increasing the authorized share pool preserves headroom for future financing, equity incentives, strategic transactions and potential anti-takeover defense.
Potential Investor Impact
- The full warrant exercise would expand the current share count by more than ten-fold, causing substantial dilution.
- Stockholders could face further dilution from any future issuances under the expanded authorization.
- Reverse splits do not change proportional ownership but often reduce liquidity and may signal financial distress.
- Failure to pass Proposal 1 obliges the company to call new meetings every 40 days, increasing cost and management distraction.
The Board unanimously recommends “FOR” on all four proposals.
Nuwellis has received a delisting notice from Nasdaq on June 18, 2025, due to non-compliance with the minimum bid price requirement of $1.00 for 30 consecutive trading days. The company is not eligible for the standard compliance period due to previous reverse stock splits.
Key developments:
- Company executed a reverse stock split on June 27, 2024
- Shareholders approved a new reverse split ratio of 1-for-5 to 1-for-70 at May 20, 2025 annual meeting
- Board intends to implement another reverse stock split to regain compliance
- Company plans to request a hearing with Nasdaq Hearings Panel
Stock will remain listed on Nasdaq Capital Market pending the hearing outcome. However, there is no guarantee of continued listing or successful compliance restoration. This situation presents significant risks for investors, including potential delisting and further share dilution through another reverse split.